Entero Therapeutics (Nasdaq:ENTO) - Hisse Senedi Fiyatı, Haberler ve Analizler

ENTO Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Entero Therapeutics, Inc. gastrointestinal hastalıkları olan hastaların tedavisi için hedefe yönelik ve ağızdan verilen tedavilerin geliştirilmesiyle ilgilenmektedir. Daha fazla detay

ENTO temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 16.2% oranında arttı

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( $2M )

+ 2 daha fazla risk

Entero Therapeutics, Inc. Rakipler

Sonnet BioTherapeutics Holdings

NasdaqCM:SONN

US$2.3m

GRI Bio

NasdaqCM:GRI

US$2.1m

Scorpius Holdings

NYSEAM:SCPX

US$2.8m

Salarius Pharmaceuticals

NasdaqCM:SLRX

US$2.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Entero Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.45
52 Haftanın En Yüksek Seviyesi	US$14.51
52 Haftanın En Düşük Seviyesi	US$0.18
Beta	1.22
11 Aylık Değişim	-21.49%
3 Aylık Değişim	8.98%
1 Yıllık Değişim	-90.53%
33 Yıllık Değişim	-99.99%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

Hissedar Getirileri

	ENTO	US Biotechs	US Pazar
7D	13.3%	4.3%	1.6%
1Y	-90.5%	18.8%	32.3%

Getiri vs. Endüstri: ENTO geçen yıl % 18.8 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ENTO geçen yıl % 32.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ENTO's price volatile compared to industry and market?
ENTO volatility
ENTO Average Weekly Movement	27.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ENTO hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ENTO 'nin haftalık oynaklığı ( 28% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	9	James Sapirstein	www.enterothera.com

Klinik aşamada bir biyofarmasötik şirketi olan Entero Therapeutics, Inc. gastrointestinal hastalıkları olan hastaların tedavisi için hedefe yönelik ve oral yolla verilen tedavilerin geliştirilmesiyle ilgilenmektedir. Şirketin boru hattı adayları arasında, şu anda Faz 2 çalışmaları altında olan, glüteni immünojenik olmayan peptitlere parçalamak için tasarlanmış çölyak hastalığı için hedeflenmiş bir oral biyoterapötik olan latiglutenaz ve gastroparezi tedavisi için Faz 1 çalışmaları altında seçici bir 5-HT4 reseptörü kısmi agonisti olan capeserod bulunmaktadır. Ayrıca, kistik fibrozis ve kronik pankreatitli hastalarda ekzokrin pankreas yetmezliğinin tedavisi için Faz 2 çalışmaları devam eden, yağların ve diğer besin maddelerinin sindirimini sağlamak üzere tasarlanmış rekombinant bir lipaz enzimi olan adrulipazın geliştirilmesinde yer almaktadır; ve ülseratif proktit ve ülseratif proktosigmoiditin yanı sıra metastatik kanser hastalarında immün kontrol noktası inhibitörüyle ilişkili kolit ve diyare tedavisi için Faz 2 çalışmaları devam eden, anti-enflamatuar inhibitör tedavisine sahip oral küçük bir molekül olan niklosamid.

Entero Therapeutics, Inc. Temel Bilgiler Özeti

Entero Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ENTO temel i̇stati̇sti̇kler
Piyasa değeri	US$2.21m
Kazançlar(TTM)	-US$8.15m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.3x

F/K Oranı

ENTO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ENTO gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$8.15m
Kazançlar	-US$8.15m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.71
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

ENTO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ENTO Stoklara Genel Bakış

Ödüller

Risk Analizi

Entero Therapeutics, Inc. Rakipler

NasdaqCM:SONN

US$2.3m

NasdaqCM:GRI

US$2.1m

NYSEAM:SCPX

US$2.8m

NasdaqCM:SLRX

US$2.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Less than half of directors are independent

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction.

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

Recent updates

Less than half of directors are independent

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction.

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis